Loading data for QCLS — first visit, this takes a few seconds.
Q/C Technologies Inc. (QCLS)
NasdaqCM: QCLS
· Real-Time Price · USD
2.49
+0.05 (2.05%)
At close: Aug 26, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Q/C Technologies Inc. (QCLS) Stock Price, Analysis & Data
2.05% (1D)
| Bid | 2.48 |
| Market Cap | 20.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.34M |
| 2.11 | |
| -93.51 | |
| n/a | |
| n/a | |
| P/B (ttm) | 1.28 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.52 |
| Volume | 129,471 |
| Avg. Volume (20D) | 230,496 |
| Open | 2.46 |
| Previous Close | 2.44 |
| Day's Range | 2.42 - 2.57 |
| 52-Week Range | 2.30 - 8.94 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About QCLS
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Su...
Industry Computer Hardware
Sector Technology
IPO Date Jan 23, 2014
Employees 3
Stock Exchange NasdaqCM
Ticker Symbol QCLS
Website https://www.qctechnologies.com
Financial Performance
In 2025, Q/C's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -11.63M, a decrease of -50.22%.
Financial Statements